EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches

Benjamin Ribba, Andreas Roller, Hans-Joachim Helms, Martin Stern, Conrad Bleul

Frontiers in Pharmacology · 08.03.2023 · 13

DOI: 10.3389/fphar.2022.1058220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.03.2023. Verfasst von Benjamin Ribba und 4 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffman-La Roche Ltd, Basel, Switzerland. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To support further development of model-informed drug development approaches leveraging circulating tumor DNA (ctDNA), we performed an exploratory analysis of the relationships between treatment-induced changes to ctDNA levels, clinical response and tumor size dynamics in patients with cancer treated with checkpoint inhibitors and targeted therapies. This analysis highlights opportunities for pharmacometrics approaches such as for optimizing sampling design strategies. It also highlights challenges related to the nature of the data and associated variability overall emphasizing the importance of mechanistic modeling studies of the underlying biology of ctDNA processes such as shedding, release and clearance and their relationships with tumor size dynamic and treatment effects.

Schlagwörter

Stichwörter der Autor:innen

cancer immunotherapiescirculating tumor DNA (ctDNA)clinical efficacyearly clinical developmentmodeling and simulation

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffman-La Roche Ltd, Basel, Switzerland.

Zitieren

APA

Ribba, B., Roller, A., Helms, H. J., Stern, M., & Bleul, C. (2023). Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1058220

Vancouver

Ribba B, Roller A, Helms HJ, Stern M, Bleul C. Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1058220

BibTeX
@article{Ribba2023,
  author = {Ribba, Benjamin and Roller, Andreas and Helms, Hans-Joachim and Stern, Martin and Bleul, Conrad},
  title = {Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fphar.2022.1058220}
}
Kostenlos starten →